Sten Stovall
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Ipsen’s Palovarotene Hit By FDA Clinical Hold
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
Freshly Funded ImCheck Goes After Gamma Delta T-Cells
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.
Macrophage Pharma Seeks Funding To Take Novel Cancer Therapy Forward
Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.
Verona Foresees FDA End-Of-Phase II COPD Meeting
Verona CEO tells Scrip Phase III COPD studies for its lead asset will start next year, take up to two years to complete, leading to commercial launch “probably in 2024.”
Targeting Liver Tumors: Ascelia CEO Expects 2022 Mangoral Launch
The CEO of Ascelia Pharma is confident of a successful pivotal trial for its non-gadolinium imaging agent for the detection of liver tumors that could benefit kidney disease patients.